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The fluorinated pyrimidine 5¢-deoxy-5-fluorouridine (5¢-dFUrd) is
the intermediate metabolite of the anticancer drug capecitabine
(Xeloda ™N4-pentyloxycarbonyl-5¢-deoxy-5-fluorocytidine), and
has been shown to reverse the wasting in the colon 26 adenocarci-
noma cachexia model (Tanaka et al, 1990), independent of its
antiproliferative activity (Eda et al, 1991). The mechanism for this
effect is not known and the mechanism by which colon 26 adeno-
carcinoma induces cachexia has not been fully elucidated. Various
cytokines have been implicated as mediators of the process of
cachexia. Of these, interleukin-6 (IL-6) has been suggested to be
most important in the colon 26 model, since serum levels of this
cytokine appeared to correlate with the development of cachexia
(Strassman et al, 1992), and administration of anti-IL-6 mono-
clonal antibody, but not anti-tumour necrosis factor-a (TNF-a)
monoclonal antibody, attenuated the development of weight loss
and other parameters of cachexia. However, other data (Fujimoto-
Ouchi et al, 1995; Soda et al, 1995) has raised doubts as to whether
IL-6 alone is responsible for cachexia in this model. Although IL-
6 mRNA was selectively detected at the tumour site of a cachexia-
inducing (clone 20) variant of the colon 26 adenocarcinoma, but
not at a non-cachexia-inducing (clone 5) variant (Yasumoto et al,
1995), serum levels of IL-6 were found to be elevated in mice
transplanted with either clone, although levels were found to be
35% lower in animals bearing clone 5 than clone 20 (Fujimoto-
Ouchi et al, 1995). This suggests that IL-6 is necessary, but not
sufficient, for the induction of cachexia in this model.
One candidate for an additional factor is a sulphated glycopro-
tein of Mr 24 000 elaborated by cachexia-inducing murine
(Todorov et al, 1997) and human tumours (Todorov et al, 1996a),
which has been shown to induce a state of cachexia when adminis-
tered to mice (Todorov et al, 1996a; Cariuk et al, 1997), associated
with a depletion of skeletal muscle protein, without a loss of
visceral protein (Lorite et al, 1998). This effect was caused by
direct catabolism of skeletal muscle proteins (Lorite et al, 1997;
Todorov et al, 1997) and for this reason the material has been
named proteolysis-inducing factor (PIF).
In the present investigation the effect of 5¢-dFUrd on the devel-
opment of cachexia and PIF levels in tumour, serum and urine has
been determined in mice bearing the colon 26 adenocarcinoma, 
as well as in those bearing a human uterine cervical carcinoma,
Yumoto, which produces a cachexia, also thought to be mediated
by IL-6 (Tamura et al, 1995). In addition the effect of this fluori-
nated pyrimidine has been determined on cachexia induced by the
MAC16 tumour for which there is no involvement of IL-6
(Mulligan et al, 1992).
MATERIALS AND METHODS
Animals
Female NMRI mice, obtained from our own colony, were trans-
planted into the flanks with fragments of the MAC16 tumour, as
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described (Beck and Tisdale, 1987), when the animals reached 6–8
weeks of age. Male BALB/c ´ DBA/2F, mice were purchased
from SLC (Hamamatsu, Japan) and transplanted subcutaneously
(s.c.) with 106 colon 26 adenocarcinoma cells into the right
inguinal flank when they reached 5 weeks of age (Tanaka et al,
1990). Animals were inoculated with either clone 20 (cachexia-
inducing) or clone 5 (which does not induce cachexia). The human
uterine cervical carcinoma, Yumoto, clone 17, was transplanted
s.c. into female BALB/c-nu/nu mice (Charles River, Japan Inc.,
Atsugi, Japan) when the animals were 6–7 weeks of age (Tamura
et al, 1995).
Chemicals and treatment
5¢-dFUrd was obtained from Nippon Roche KK (Tokyo, Japan).
The compounds were administered orally (p.o) suspended in either
0.5% carboxymethylcellulose (colon 26 and Yumoto), or liquid
paraffin (MAC16), at the concentrations and time schedules
shown. Control groups received vehicle alone. The group sizes
comprised either six animals (colon 26) or ten animals (MAC16
and Yumoto). The fluorinated pyrimidine was administered daily
from day 13 until 20 (colon 26), days 36–40 and 43–46 (Yumoto)
and days 12–17 (MAC16). For MAC16, body weight and tumour
volume were determined daily during the treatment. Tumour
dimensions were measured by means of calipers and the volume
was calculated from the formula:
Animals were terminated when the body weight reached 75% of
their starting weight.
Urine samples were collected from mice with colon 26 tumours
using metabolic cages on day 13 (before treatment) and day 20
(after treatment), and from mice with Yumoto tumours on day 26
(before treatment) and day 47 (after treatment). At the end of the
experiment the animals were humanely killed and serum and
organ samples were collected and weighed.
Sample preparation
Tumours were homogenized in 10 mM Tris–HCl, pH 8.0,
containing 0.5 mM phenylmethylsulphonyl fluoride, 0.5 mM
EGTA and 1 mM dithiothreitol (DTT). The supernatant, obtained
by low speed centrifugation (4000 rpm for 15 min on a benchtop
centrifuge), was precipitated with ammonium sulphate (40% w/v)
with stirring at 4°C. The precipitate was removed by centrifuga-
tion (4500 rpm for 20 min) and the supernatant was concentrated
against phosphate buffered saline (PBS) using a Microcon micro-
concentrator containing a membrane filter with a molecular weight
cut-off of Mr 10 000 (Amicon Inc., Beverly, MA, USA). The
supernatant was applied overnight to an affinity column
containing monoclonal antibody coupled to Affi Gel Hz (Bio-Rad,
Hemel Hempstead, UK (17) and active fractions were eluted with
100 mM glycine. HCl, pH 2.5, neutralized with 1 M Tris–HCl,
ultrafiltered against water using an Amicon filtration cell and used
for Western blotting. Serum samples were passed through a
protein A-sepharose column to remove antibodies and then
subjected to affinity chromatography as above. Urine was treated
with ammonium sulphate (80% w/v) and stirred overnight at 4°C.
The precipitated protein was recovered by centrifugation at 3000 g
for 30 min, dialysed against water using an Amicon filtration cell
and used for Western blotting.
Western blot analysis
Samples (5 mg protein) were loaded onto sodium dodecyl sulphate
polyacrylamide gels consisting of a 5% stacking gel and a 
15% resolving gel (Cariuk et al, 1997). Gels were transferred to
nitrocellulose membranes (Hoefer Scientific Instruments, San
Francisco, CA, USA) which had been blocked with 5% Marvel in
0.15% Tween-20 in PBS at 4°C overnight. The membranes were
washed once for 15 min in 0.5% Tween-20 in PBS, followed by
two more washes. The membranes were incubated for 1 h at room
temperature in Tween/PBS containing 1.5% Marvel and mono-
clonal antibody (10 mg ml–1) (Todorov et al, 1996b) which had
been biotinylated using the enhanced chemiluminescence (ECL)
protein biotinylation module (Amersham UK). After being
washed three times as above, the filters were incubated for 1 h at
room temperature with streptavidin–horseradish peroxidase conju-
gate (Amersham) at a 1- to 1500-fold dilution followed by three
15-min washes with 0.1% Tween in PBS. Bands were detected
with an ECL system (Amersham).
Statistical analysis
Differences between groups were analysed by the Mann–Whitney
U-test or ANOVA followed by Tuckey’s test. The level of
significance was regarded as P < 0.05.
RESULTS
The effect of daily p.o. administration of 5¢-dFUrd, suspended in
liquid paraffin, on changes in body weight and tumour growth rate
in mice bearing the MAC16 tumour is shown in Figure 1. Control
non-tumour-bearing animals did not significantly change in
weight during the time course of Figure 1 and these data are not
included. There was no difference in the rate of weight loss
between vehicle-treated mice and an untreated group, but a dose-
related reduction in the rate of weight loss in animals treated with
5¢-dFUrd, which became significant at dose levels of 0.44 and 
0.88 mmol kg–1 day–1 (Figure 1A). There was no difference in food
or water intake between the groups (Table 1). There was a small
inhibition of tumour growth rate, but this was only significant at a
dose level of 0.44 mmole kg–1 day–1 (Figure 1B) and there was 
no significant difference in the tumour wet weights (Table 1). The
inhibition of tumour growth rate was not sufficient to account for
the preservation of body weight.
Length ´ (width)2
2
Table 1 Effect of 5¢-dFUrd on food and water intake and final tumour
weights in mice bearing the MAC16 adenocarcinomaa
Group Food (g 24 h–1) Water (ml 24 h–1) Tumour wet
weight (g)
Non-treated 3.51 ± 0.02 3.00 ± 0.61 0.33 ± 0.05
Vehicle 3.45 ± 0.38 3.20 ± 0.58 0.44 ± 0.04
5¢-dFUrd mmole kg–1 day–1
0.11 3.60 ± 0.16 3.27 ± 0.21 0.36 ± 0.03
0.22 3.72 ± 1.09 2.89 ± 0.75 0.35 ± 0.04
0.44 3.46 ± 0.09 2.80 ± 0.69 0.25 ± 0.06
0.88 3.40 ± 0.20 3.20 ± 0.29 0.32 ± 0.07
aValues are expressed as mean ± s.e.m. for ten animals per group.58 HJ Hussey et al
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The effect of 5¢-dFUrd on tumour and body weight change in
mice transplanted with murine colon 26 adenocarcinoma cells,
clone 20 and clone 5 and the human cervical carcinoma, Yumoto is
shown in Table 2. As previously reported (Fujimoto-Ouchi et al,
1995) colon 26 and clone 20, produced profound cachexia with a
decrease in body weight arising from a loss of both adipose tissue
and muscle mass, while clone 5 produced no change in body
weight or muscle mass, even though the total tumour mass at day
21 was threefold greater in animals bearing the clone 5 variant
than the clone 20 (Table 2). However, clone 5 did produce a signi-
ficant depression of adipose tissue when compared with the non-
tumour-bearing group. As in the MAC16 model 5¢-dFUrd at 
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Figure 1 The effect of daily oral administration of either vehicle (´) or 5¢-dFUrd at 0.11 (l l), 0.22 (l), 0.44 (s s) or 0.88 (s) mmoles kg–1 day–1 on body weight
(A) and tumour volume (B) in mice bearing the MAC16 tumour. The results are shown as mean ± s.e.m., where n = 10. Differences from vehicle-treated controls
are shown as (a) P < 0.05; and (b) P < 0.01 using two-way ANOVA followed by Tuckey’s testAnticachectic fluorinated pyrimidine 59
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0.5 mmole kg–1 day–1 suppressed the loss of body weight, adipose
tissue and gastrocnemius muscle in animals bearing clone 20
tumours, while reducing tumour burden in mice bearing both the
clone 20 and clone 5 variants. In the Yumoto model 5¢-dFUrd also
effectively suppressed tumour development and attenuated the
development of cachexia at the higher dose. Previous studies with
5¢-dFUrd have indicated that the recovery from cachexia is not the
result of the reduction in tumour size (Eda et al, 1991).
To determine whether 5¢-dFUrd had any effect on factors that
may be responsible for the cachexia, urine, serum and tumour
samples were probed by Western blotting for changes in the
production of PIF. The results from urine samples of mice bearing
the colon 26 tumour are shown in Figure 2. We have previously
reported that PIF occurs in a free from of Mr 24 000 and an
albumin bound form of Mr 69 000 (Todorov et al, 1996a). Animals
bearing clone 20 tumours showed evidence for the excretion of
both forms of PIF on day 13 (Figure 2, lane 1) and this was also
seen in vehicle-treated control mice on day 20 (Figure 2, lane 4).
Treatment with 5¢-dFUrd (Figure 2, lane 5) resulted in the
complete abolition of the excretion of both forms of PIF. In
contrast with these results in mice bearing the clone 20 variant,
mice bearing colon 26, clone 5, showed no evidence for the excre-
tion of either form of PIF either on day 13 (Figure 2, lane 2) or day
20 (Figure 2, lanes 6 and 7). A Western blot of urine from mice
bearing the Yumoto tumour is shown in Figure 3. Again control
animals at day 26 (Figure 3, lane 1) and vehicle treated controls at
day 47 (Figure 3, lane 2) showed evidence for the excretion of PIF,
although in this case only the albumin bound form was observed.
Treatment with 5¢-dFUrd at the lower dose level (Figure 3, lane 3),
caused a substantial reduction in the intensity of the Mr 69 000
band, while at the higher dose level it was completely absent
(Figure 3, lane 4).
Table 2 Effect of 5¢-dFUrd on tumour, body weight, adipose and gastrocnemius muscle mass between days 13 and 21 (colon 26)a and days 26 and 47
(Yumoto)b
Tumour type Treatment Tumour (mg) Body weight (g) Adipose (mg)c Gastrocnemius (mg)
Colon 26, clone 20 Before (day 13) 244 ± 17 24.9 ± 1.3 155 ± 30 136 ± 9
Non-tumour bearing (day 21) – 27.8 ± 1.7 228 ± 53 171 ± 17
Vehicle (day 21) 279 ± 28h 20.3 ± 3.5j 24 ± 31k 110 ± 11m
5¢-dFUrd (day 21)d 174 ± 26f 23.5 ± 2.1g 67 ± 46f 125 ± 18
Colon 26, clone 5 Before (day 13) 295 ± 85 26.7 ± 0.8 204 ± 39 149 ± 7
Vehicle (day 21) 863 ± 184i 27.2 ± 1.1 118 ± 19k 157 ± 11
5¢-dFUrd (day 21)d 432 ± 114f 25.5 ± 0.4 129 ± 54j 157 ± 23
Yumoto, clone 17 Before (day 26) 470 ± 168 20.6 ± 1.2 15.4 ± 9.6 88.5 ± 19.8
Non-tumour bearing (day 47) – 21.6 ± 1.1 49.1 ± 20.3 112.8 ± 13.0
Vehicle (day 47) 1157 ± 294 19.6 ± 1.9k 11.1 ± 8l 88.2 ± 11.5n
5¢-dFUrd (day 47)d 713 ± 264f 20.8 ± 1.5 19.8 ± 11.5 97.6 ± 8.8f
5¢-dFUrd (day 47)e 655 ± 175f 21.1 ± 1.4f 27.3 ± 25.6f 99.2 ± 12.3f
a Results are expressed as mean ± s.d. for six mice per group; b Results are expressed as mean ± s.d. for ten mice per group; c Epididymal adipose tissue
for colon 26 and periovarian for Yumoto; d 0.5 mmol kg–1 day–1; e 1.0 mmol kg–1 day–1; f P < 0.05 compared with vehicle-treated group; g P = 0.05 from vehicle-
treated group; h P = 0.05 from day 13; i P = 0.004 from day 13; j P = 0.01 from non-tumour bearing group; k P = 0.003 from non-tumour bearing group; 
P = 0.0002 from non-tumour bearing group; m P = 0.007 from non-tumour bearing group; n P = 0.002 from non-tumour bearing group.
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Figure 2 Immunoblot of urine from mice bearing colon 26 adenocarcinoma.
Lane 1, clone 20, day 13; lane 2, clone 5, day 13; lane 3, empty; lane 4,
clone 20, day 20, vehicle; lane 5, clone 20, day 20, 0.5 mmole kg–1 day–1
5¢-dFUrd; lane 6, clone 5, day 20 vehicle; lane 7, clone 5, day 20, 
0.5 mmole kg–1 day–1 5¢-dFUrd; lane 8, empty
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Figure 3 Immunoblot of urine from mice bearing Yumoto tumour. Lane 1,
day 26; lane 2, day 47, vehicle; lane 3, day 47, 0.5 mmole kg–1
day–1 5¢-dFUrd; lane 4, day 47, 1.0 mmole kg–1 day–1 5¢-dFUrd60 HJ Hussey et al
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Similar results were obtained using serum from tumour-bearing
mice (Figures 4 and 5). No immunoreactive bands were observed
in serum from non-tumour-bearing mice (Figure 4, lanes 1 and 2),
while serum from mice bearing colon 26, clone 20 showed a strong
positive band at Mr 24 000 (Figure 4, lane 3), which was
completely absent in mice treated with 5¢-dFUrd (Figure 4, lane 5).
As for urine, serum from mice bearing the clone 5 variant showed
no evidence for the presence of PIF in the presence or absence of
5¢-dFUrd (Figure 4, lanes 6–8). Serum from mice bearing the
Yumoto tumour also showed evidence for the Mr 24 000 form of
PIF (Figure 5, lanes 1 and 2), and this completely disappeared
from the serum of mice treated with 5¢-dFUrd (Figure 5, lanes 3
and 4). It is not known why the free form of PIF is present in the
serum, while the albumin bound form is present in the urine, but
may be related to transport through the kidneys.
When colon 26 and Yumoto tumours were probed for the pres-
ence of PIF the results paralleled that found in serum and urine
(Figures 6 and 7). Thus colon 26, clone 20, showed evidence for
expression of the albumin bound form of PIF (Figure 6, lane 1) and
this was not evident in clone 5 tumours (Figure 6, lane 2). Both
forms of PIF disappeared from clone 20 tumours treated with
5¢-dFUrd (Figure 6, lanes 3 and 4). Yumoto tumours also showed
evidence for the presence of PIF (Figure 7, lane 1), while this
was absent from tumours treated with 5¢-dFUrd (Figure 7, lanes 3
and 4).
DISCUSSION
This study shows that 5¢-dFUrd is an effective inhibitor of
cachexia in three animal models tested; MAC16 and colon 26 as
well as the xenotransplanted tumour, Yumoto. Capecitabine, a
prodrug of 5¢-dFUrd also showed anti-cachectic activity in the
MAC16 model (results not shown). Anti-cachectic activity in the
MAC16 model was seen at concentrations producing minimal
inhibition of tumour growth. The MAC16 tumour is generally
refractory to most cytostatic drugs including 5-FU (Double and
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Figure 4 Immunoblot of serum from mice bearing colon 26
adenocarcinoma. Lane 1, non-tumour-bearing, day 13; lane 2, non-tumour-
bearing, day 20; lane 3, clone 20, day 13; lane 4 empty; lane 5, clone 20, day
20, 0.5 mmole kg–1 day–1 5¢-dFUrd; lane 6, clone 5, day 13; lane 7, clone 5,
day 20 vehicle; lane 8, clone 5, day 20, 0.5 mmole kg–1 day–1 5¢-dFUrd;
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Figure 5 Immunoblot of serum from mice bearing the Yumoto tumour. 
Lane 1, day 47 vehicle; lane 2, day 47, vehicle; lane 3, day 47, 5¢-dFUrd 
0.5 mmole kg–1 day–1; lane 4, day 47, 5¢-dFUrd, 1.0 mmole kg–1 day–1
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Figure 6 Immunoblot of colon 26 adenocarcinoma. Lane 1, clone 20, day
16; lane 2, clone 5; lanes 3 and 4, clone 20, day 23 after 5¢-dFUrd at
0.3 mmole kg–1 day–1 (lane 3) and 0.5 mmole kg–1 day–1 (lane 4)
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Figure 7 Immunoblot of Yumoto tumour. Lane 1, untreated; lane 2, empty;
lane 3, 5¢-dFUrd 0.5 mmole kg–1 day–1; lane 4, 5¢-dFUrd 1.0 mmole kg–1 day–1Anticachectic fluorinated pyrimidine 61
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Bibby, 1989). This suggests that 5¢-dFUrd may interfere with the
mediator(s) of cachexia in these animal models.
Knowledge of the mechanism by which tumours induce a
cachectic state is essential to the development of effective
inhibitors. While cytokines such as TNF-a (Beutler and Cerami,
1986), IL-6 (Strassman et al, 1995), IL-1 (Moldawer et al, 1988),
interferon-g (IFN-g) (Matthys et al, 1991) and leukaemia
inhibitory factor (LIF) (Mori et al, 1991) have been implicated as
mediators of the cachectic process in some animal models there is
little data to substantiate their playing a major role in human
cancer cachexia. In contrast, in a study of 47 patients with carci-
noma of the lung, pancreas, breast, ovary, colon, rectum and liver
(Cariuk et al, 1997), PIF was detected in the urine of all patients
with a weight loss greater than 1 kg month–1, but was not present in
the urine of patients with the same type of tumour who were
weight-stable. Patients with weight loss due to surgery, sepsis,
multiple injuries, burns, acute pancreatitis and sleeping sickness
showed no evidence for excretion of PIF in the urine. This
suggests that PIF may play a more important role in human cancer
cachexia than the cytokines.
Thus although there is considerable evidence to support a role
for IL-6 in the development of cachexia in the colon 26 adenocar-
cinoma model (Strassman et al, 1995), most workers suggest that
it is unlikely to act alone, but may induce or work in synergy with
other cachectic factors (Fujiki et al, 1997; Fujimoto-Ouchi et al,
1995; Soda et al, 1995). This study provides support that this
factor may be PIF, both in the colon 26 and Yumoto models. Thus
in colon 26, clone 20, which induces cachexia, there is evidence
for the presence of PIF in tumour, serum and urine, while in clone
5, which does not induce cachexia, there is no evidence for PIF in
either the tumour serum or urine. Interestingly clone 5 does cause
loss of adipose tissue, suggesting production of a lipid mobilizing
factor (LMF) in the absence of PIF (Todorov et al, 1998). The
Yumoto tumour also shows the presence of PIF, as does serum and
urine from mice transplanted with this tumour. Further evidence to
support a role of PIF in the development of cachexia in these
models is provided by the anti-cachectic agent 5¢-dFUrd. Thus in
mice bearing colon 26, clone 20 tumours, treated with 5¢-dFUrd
there was a complete disappearance of PIF from tumour, serum
and urine coincident with the attenuation of the development of
cachexia. Similar data was obtained from mice bearing Yumoto
tumours.
These results suggest that 5¢-dFUrd may interfere with the
biosynthesis of PIF and that this may be responsible for the anti-
cachectic activity. Although 5¢-dFUrd also causes suppression of
tumour growth previous studies have shown that the anti-cachectic
effect is distinct from the antiproliferative activity. Thus 5¢-dFUrd
immediately reversed the development of cachexia even at doses
allowing tumour growth (Eda et al, 1991). In sublines of colon 26
which were resistant to the anti-cachectic effect of 5¢-dFUrd,
growth inhibition was still observed (Eda et al, 1991). This
suggests that 5¢-dFUrd may inhibit the production of substances
triggering the development of cachexia.
Very few agents have been demonstrated to have true anti-
cachectic activity. However, one such agent, eicosapentaenoic acid
(EPA) has been shown to attenuate the development of cachexia,
both in the MAC16 model (Beck et al, 1991) and in patients with
unresectable pancreatic cancer (Wigmore et al, 1996). The effect
of EPA in counteracting skeletal muscle protein degradation has
been attributed to the ability to antagonise the action of PIF (Lorite
et al, 1997). This suggests that future agents aimed at alleviating
cancer cachexia should be directed more towards the action of PIF
than the cytokines.
This study has shown 5¢-dFUrd to display profound anti-
cachectic activity in two murine and one human model. Further
studies will be directed towards the evaluation of this agent and
capecitabine in human cancer cachexia.
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